CBD alongside blood pressure medication: my daily experience with metoprolol and lisinopril
Bottom line. I take metoprolol and lisinopril every day. I also take CBD every day. This isn't theoretical, I'm navigating this combination right now. Here's what I watch for and what the science says: the CBD-antihypertensive interaction has two distinct mechanisms. First, many BP medications (calcium channel blockers in particular) are CYP3A4-metabolized, and CBD inhibits CYP3A4, which can raise medication plasma levels. Metoprolol uses CYP2D6; lisinopril is not significantly CYP-metabolized, so the pharmacokinetic concern is lower for those two specifically. Second, CBD itself lowers resting blood pressure acutely (Jadoon 2017), creating additive BP-lowering on top of your medication. I monitor my BP regularly. Tell your prescriber what you're taking.
Key takeaways
- Metoprolol uses CYP2D6 (CBD inhibits this); lisinopril is not significantly CYP-metabolized, so my combination has lower pharmacokinetic risk than calcium channel blockers would.
- The additive BP-lowering concern applies to all antihypertensive classes: CBD lowers resting BP acutely (Jadoon 2017), and that stacks with medication.
- Calcium channel blockers (amlodipine, nifedipine) have the highest pharmacokinetic concern, CYP3A4 primary metabolism, CBD inhibits CYP3A4.
- What to watch for: dizziness or lightheadedness when standing (orthostatic hypotension), especially in the first weeks after starting CBD.
- A home BP cuff is inexpensive. I use one. Take readings at consistent times before and after starting CBD.
The two mechanisms explained
Mechanism 1 - CYP3A4 inhibition
Plain version: CBD can cause certain blood pressure medications to build up to higher-than-intended levels in your blood, because CBD slows the enzyme (CYP3A4) your body uses to clear them. Higher medication levels mean stronger blood-pressure-lowering effects.
Several antihypertensive drug classes rely heavily on CYP3A4: calcium channel blockers (amlodipine, nifedipine, felodipine, diltiazem, verapamil) are the clearest examples. Bansal 2023 confirmed CBD raises CYP3A substrate plasma exposure 56–207%. If amlodipine levels rise, the blood-pressure-lowering effect of the medication intensifies — compounding on top of CBD's own direct BP effect.
Mechanism 2 - direct blood pressure lowering
Jadoon 2017 - a randomized, double-blind, placebo-controlled crossover trial in 9 healthy male volunteers , found a single 600mg CBD dose lowered resting systolic BP by ~6 mmHg and attenuated the BP rise from stress. The mechanism is likely vasodilation via CBD's action on TRPV1 and arterial relaxation pathways. At wellness doses (25–50mg), the BP effect is smaller than the 600mg dose in Jadoon — but the direction is the same, and it stacks with medication.
Antihypertensive classes and their interaction profile
| Drug class | Examples | CYP metabolism | CBD concern |
|---|---|---|---|
| Calcium channel blockers | Amlodipine, nifedipine | CYP3A4 (high) | PK + additive BP |
| Beta-blockers | Metoprolol, carvedilol | CYP2D6 | PK (2D6) + additive BP |
| ACE inhibitors | Lisinopril, enalapril | Minimal CYP | Additive BP only |
| ARBs | Losartan, valsartan | CYP2C9 (losartan) | Additive BP; minor PK |
| Diuretics | HCTZ, furosemide | Minimal CYP | Additive BP only |
What this means for you
- Tell your prescriber before starting CBD. Mention your antihypertensive class and dose. Ask whether more frequent BP monitoring makes sense in the first few weeks.
- Monitor your blood pressure. A home BP cuff is inexpensive. Take readings at consistent times before and after starting CBD. If systolic drops more than 10–15 mmHg or you feel dizzy when standing, contact your prescriber.
- Watch for orthostatic hypotension. Dizziness or lightheadedness when standing up from sitting or lying is the most common symptom of excessive BP lowering — especially relevant in adults over 60. If you experience fainting, chest pain, sudden severe headache, difficulty speaking, or loss of limb function, call 911 (or your local emergency number) immediately — do not wait to contact your prescriber, as these can signal a stroke or cardiac event.
- Titrate CBD slowly. Starting at 10–15mg and holding 5–7 days before increasing (see the titration protocol) lets you track any BP changes gradually rather than introducing a large variable at once.
- Consider the topical for localized use. If you want CBD primarily for joint or muscle pain and your prescriber prefers minimal systemic exposure, the topical roll-on has negligible CYP and direct BP impact.
Frequently asked questions
Can CBD lower my blood pressure too much if I'm already on medication?
It's a real concern worth monitoring, not a reason to avoid CBD, but a reason to pay attention. Jadoon 2017 showed a single 600mg CBD dose lowered resting systolic BP by ~6 mmHg in healthy volunteers. At the 25–50mg wellness doses I use, the effect is smaller, but the direction is the same, and it stacks with antihypertensive medication. I use a home BP cuff and take readings regularly. Tell your prescriber what you're on.
Does CBD raise or lower blood pressure?
CBD lowers resting blood pressure acutely (Jadoon 2017). The effect is dose-dependent and may diminish with repeated use, that's my experience at wellness doses over time. But directionally, CBD is a BP-lowering agent when you're starting out, and that's what matters when you're also on antihypertensives.
Which blood pressure medications interact most with CBD?
From a pharmacokinetic standpoint: calcium channel blockers (amlodipine, nifedipine, felodipine) are the highest concern, they're primarily CYP3A4-metabolized and CBD inhibits CYP3A4 significantly. Metoprolol uses CYP2D6, which CBD also inhibits but less potently. Lisinopril (which I take) is not significantly CYP-metabolized, lower pharmacokinetic risk. The additive BP-lowering concern from CBD's direct effect applies across all classes regardless.
References
- Jadoon KA et al. (2017). A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. PMID 28539479
- Bansal S et al. (2023). Cannabidiol effects on the pharmacokinetics of substrates of cytochrome P450 enzymes. PMID 37313955
- Stöllberger C, Finsterer J. (2023). Interactions between cannabidiol and commonly used prescription drugs. PMID 37541924